USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ANTIOP, INC.
City: LEXINGTON
State: KY
Zip+4: 40515-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $239,908.00 1
STTR Phase II $4,206,273.00 2

Award List:

Intranasal Naloxone: An Opioid Overdose Antidote

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: University Of Kentucky
Principal Investigator: Daniel P. Wermeling – 859-323-7499
Award Amount: $239,908.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): There is a significant unmet medical need to provide additional pharmacologic treatments for treatment and prevention of opioid overdose. This Fast Track STTR project proposes to apply drug delivery technologies to develop a novel use for a nasally delivered… More

Intranasal Naloxone: An Opioid Overdose Antidote

Award Year / Program / Phase: 2011 / STTR / Phase II
Agency: HHS
Research Institution: UNIVERSITY OF KENTUCKY
Principal Investigator: Daniel P. Wermeling – (859) 221-4138
Award Amount: $1,219,884.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): There is a significant unmet medical need to provide additional pharmacologic treatments for treatment and prevention of opioid overdose. This Fast Track STTR project proposes to apply drug delivery technologies to develop a novel use for a nasally delivered… More

Naloxone Nasal Spray Development

Award Year / Program / Phase: 2013 / STTR / Phase II
Agency: HHS
Research Institution: UNIVERSITY OF KENTUCKY
Principal Investigator: Daniel P. Wermeling – 859-323-7499
Award Amount: $2,986,389.00
RI Contact:
Abstract:
DESCRIPTION: The following proposal is a follow-on Phase 2 b application from our initial proposal (1-R42 DA 030001). U.S. drug overdose deaths, mostly commonly from opioids, now exceed deaths from automobile accidents. There is a significant unmet medical need to provide additional pharmacologic… More